Bulk Pharmaceutical API Sources for BRINZOLAMIDE

Bulk Pharmaceutical API Sources for BRINZOLAMIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-5277
Molport		MolPort-005-940-291
AKos Consulting & Solutions		AKOS005145708
AbaChemScene		CS-2788
MedChemexpress MCE		HY-B0588

Brinzolamide Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report details the current landscape of bulk active pharmaceutical ingredient (API) sourcing for Brinzolamide, a carbonic anhydrase inhibitor used to treat glaucoma. Analysis focuses on key manufacturers, geographical distribution, regulatory status, and pricing trends to inform R&D and investment decisions.

What is Brinzolamide API and its Application?

Brinzolamide is a sulfonamide derivative that inhibits carbonic anhydrase II, an enzyme found in the ciliary processes of the eye. Inhibition of this enzyme reduces the formation of bicarbonate ions, which subsequently decreases aqueous humor secretion. Reduced aqueous humor flow leads to a decrease in intraocular pressure (IOP). Brinzolamide is approved for the topical treatment of elevated IOP in patients with open-angle glaucoma or ocular hypertension.

The chemical name for Brinzolamide is (R)-4-Ethylamino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide. Its molecular formula is C12H21N3O5S3, and its molecular weight is 383.51 g/mol.

Who are the Major Brinzolamide API Manufacturers?

The global supply of Brinzolamide API is concentrated among a limited number of manufacturers, primarily located in India and China. These entities specialize in complex organic synthesis and operate under strict Good Manufacturing Practice (GMP) guidelines to meet regulatory requirements for pharmaceutical ingredient production.

Key Brinzolamide API suppliers include:

• Centaur Pharmaceuticals Pvt. Ltd. (India): A significant player in generic API manufacturing, Centaur is known for its strong R&D capabilities and established manufacturing facilities.
• Laurus Labs Limited (India): Laurus Labs is a globally recognized API manufacturer with a diversified portfolio. They have demonstrated capabilities in producing complex APIs, including ophthalmological agents.
• Divi's Laboratories Limited (India): Divi's is a leading custom synthesis and generic API manufacturer. Their large-scale production capacity and regulatory compliance make them a key supplier.
• Zydus Lifesciences Limited (formerly Cadila Healthcare) (India): Zydus offers a broad range of APIs, including those for ophthalmic indications, backed by robust manufacturing and quality control systems.
• Jiangsu Hengrui Medicine Co., Ltd. (China): A prominent Chinese pharmaceutical company with substantial API manufacturing capacity. Hengrui is a significant global supplier across various therapeutic areas.
• Wuhan Yuancheng Gongchuang Technology Co., Ltd. (China): This company is active in the chemical and pharmaceutical intermediate sector, potentially supplying Brinzolamide API or key intermediates.

The market is characterized by a few dominant players, creating a competitive but somewhat consolidated supply chain. Decisions regarding supplier selection require thorough due diligence on quality, reliability, and regulatory adherence.

What is the Geographical Distribution of Brinzolamide API Production?

The production of Brinzolamide API is predominantly concentrated in Asia, with India and China leading the global supply. This geographical concentration is driven by several factors, including established expertise in complex chemical synthesis, cost-effective manufacturing environments, and significant investment in pharmaceutical infrastructure.

• India: Home to several major API manufacturers, India has a well-developed pharmaceutical industry with a strong focus on generic drug production. Companies in India have invested heavily in advanced manufacturing technologies and stringent quality control systems to meet international regulatory standards.
• China: China's API manufacturing sector has grown exponentially, becoming a critical hub for chemical synthesis. Chinese manufacturers offer competitive pricing and possess the capacity for large-scale production. Regulatory oversight and quality assurance in China have been progressively strengthened in recent years.

Other regions, such as Europe and North America, have a smaller footprint in bulk Brinzolamide API manufacturing. While these regions possess high-quality manufacturing capabilities, the economic drivers for high-volume generic API production often favor Asian countries.

What are the Regulatory Requirements for Brinzolamide API?

The production and supply of Brinzolamide API are subject to rigorous regulatory scrutiny by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is paramount. Manufacturers must adhere to guidelines set by agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies.

Key regulatory considerations include:

• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. A DMF is a submission to regulatory authorities that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the information without having direct access to it.
• Site Inspections: Manufacturing facilities are subject to routine inspections by regulatory agencies to ensure ongoing compliance with GMP standards. Successful inspection outcomes are critical for API suppliers to maintain market access.
• Quality Control and Assurance: Robust quality control (QC) and quality assurance (QA) systems are mandatory. This includes comprehensive testing of raw materials, in-process materials, and the final API to ensure purity, potency, and consistency.
• Impurity Profiling: Detailed characterization and control of impurities, including genotoxic impurities, are critical. Regulatory agencies require comprehensive data on the impurity profile of the API.
• Stability Studies: Manufacturers must conduct comprehensive stability studies to determine the re-test period or shelf life of the API under specified storage conditions.
• Traceability: End-to-end traceability of raw materials, manufacturing processes, and distribution is essential for supply chain integrity and regulatory compliance.

API manufacturers serving regulated markets (e.g., the U.S., EU, Japan) must demonstrate a robust quality management system and a history of successful regulatory audits.

What are the Current Pricing Trends and Factors Influencing Cost?

Brinzolamide API pricing is influenced by several dynamic factors:

• Manufacturing Costs: Raw material prices, labor costs, energy expenses, and the complexity of the synthesis process directly impact the cost of API production.
• Scale of Production: Larger batch sizes generally lead to lower per-unit production costs due to economies of scale. Manufacturers with higher throughput can offer more competitive pricing.
• Regulatory Compliance Costs: Investment in maintaining GMP compliance, undergoing audits, and preparing DMFs adds to the overall cost of API production.
• Supply and Demand Dynamics: Market demand for Brinzolamide-containing formulations and the available supply of API from manufacturers influence pricing. Shortages or increased demand can lead to price increases.
• Competition: The number of qualified API suppliers in the market affects price competition. A more competitive market typically results in lower prices.
• Geographical Origin: Manufacturing location plays a role, with producers in India and China often offering competitive pricing due to lower operational costs.
• Contractual Agreements: Long-term supply agreements and volume commitments can lead to more favorable pricing for pharmaceutical companies.

Current indicative pricing for Brinzolamide API can range widely based on supplier, volume, and purity specifications. However, for bulk quantities (e.g., multi-kilogram to ton quantities), prices can range from approximately $150 to $400 per kilogram. This range is subject to significant fluctuation based on market conditions and specific supplier negotiations.

The trend is towards competitive pricing from established Indian and Chinese manufacturers who have demonstrated consistent quality and regulatory compliance. However, potential supply chain disruptions, geopolitical factors, and evolving regulatory landscapes can introduce volatility into these price trends.

What are the Intellectual Property Considerations?

Brinzolamide was originally developed by Alcon (now part of Novartis). The primary composition of matter patents for Brinzolamide have expired in major markets, paving the way for generic competition.

• Composition of Matter Patents: These patents, covering the molecule itself, are generally expired. For example, U.S. Patent 5,378,704 expired in 2010.
• Formulation Patents: Patents covering specific ophthalmic formulations, delivery systems, or combination therapies involving Brinzolamide may still be in force. These can impact the launch of new generic products or branded line extensions.
• Process Patents: Patents relating to novel or improved methods of synthesizing Brinzolamide may exist. Manufacturers must ensure their production processes do not infringe on any valid process patents.

Generic manufacturers seeking to enter the market must conduct thorough freedom-to-operate (FTO) analyses to identify and navigate any remaining intellectual property barriers. This includes evaluating patents related to the API, its manufacturing processes, and its therapeutic uses.

What are the Future Trends and Challenges in Brinzolamide API Sourcing?

The Brinzolamide API market will continue to be shaped by several key trends and challenges:

• Increasing Demand for Generics: As patents expire and healthcare costs remain a focus, the demand for affordable generic Brinzolamide formulations is expected to rise. This will drive demand for bulk API.
• Supply Chain Resilience: Recent global events have highlighted the importance of diversified and resilient supply chains. Companies may seek to qualify multiple API suppliers across different geographies to mitigate risks of disruption.
• Continuous Quality Improvement: Regulatory expectations regarding API quality, impurity control, and data integrity are continually evolving. Manufacturers must invest in advanced analytical techniques and robust quality management systems to stay ahead.
• Emerging Markets: Growth in pharmaceutical markets in emerging economies presents opportunities for increased Brinzolamide API demand as access to glaucoma treatment expands.
• Sustainability Initiatives: Increasing focus on environmental, social, and governance (ESG) factors may influence supplier selection. Manufacturers with demonstrable commitments to sustainable practices could gain a competitive advantage.
• Technological Advancements: Innovations in chemical synthesis, such as continuous manufacturing or biocatalysis, could potentially lead to more efficient and cost-effective Brinzolamide API production, though widespread adoption may take time.
• Regulatory Harmonization: Efforts towards global regulatory harmonization could simplify the process for API manufacturers seeking approval in multiple markets, but differences in national regulations will persist.

Challenges include maintaining consistent quality across diverse manufacturing sites, managing price pressures from a competitive generic market, and navigating the evolving regulatory landscape.

Key Takeaways

• Brinzolamide API supply is concentrated among manufacturers in India and China, with key players including Centaur Pharmaceuticals, Laurus Labs, Divi's Laboratories, Zydus Lifesciences, and Jiangsu Hengrui Medicine.
• Regulatory compliance, particularly GMP standards and DMF submissions, is critical for API manufacturers supplying to regulated markets.
• Indicative bulk API pricing ranges from $150 to $400 per kilogram, influenced by manufacturing costs, scale, competition, and supply dynamics.
• Original composition of matter patents for Brinzolamide have expired, facilitating generic competition, but vigilance regarding formulation and process patents is necessary.
• Future trends point to increased demand for generics, a focus on supply chain resilience, and continuous quality improvement driven by evolving regulatory expectations.

Frequently Asked Questions

1. What are the primary risks associated with sourcing Brinzolamide API from a single supplier? The primary risks include supply chain disruptions due to unforeseen events (e.g., natural disasters, geopolitical issues, plant shutdowns), potential price increases if the supplier gains market leverage, and quality control issues if the supplier's standards degrade.

2. How can a company ensure the quality and regulatory compliance of a Brinzolamide API supplier located in China or India? Companies can ensure quality and compliance through rigorous supplier qualification programs, including on-site audits of manufacturing facilities, review of quality management systems, assessment of regulatory inspection history (e.g., FDA, EMA), and verification of DMF status and content. Establishing robust testing protocols for incoming API batches is also essential.

3. Are there any significant upcoming patent expiries that could impact Brinzolamide API pricing or availability? The primary composition of matter patents for Brinzolamide have already expired. Future impacts on pricing and availability would likely stem from the expiration of key formulation patents or patents on novel manufacturing processes, which could allow for additional generic entrants or more cost-effective production methods.

4. What is the typical lead time for securing a large order of Brinzolamide API from a qualified manufacturer? Typical lead times for large orders of Brinzolamide API can range from 8 to 16 weeks from order placement to delivery. This timeframe accounts for manufacturing scheduling, production, quality control testing, and logistics. However, this can vary based on the manufacturer's current production schedule, order volume, and existing inventory.

5. Besides India and China, are there other significant regions developing Brinzolamide API manufacturing capabilities? While India and China dominate bulk API production, some specialized chemical synthesis companies in Europe and North America may offer high-purity, smaller-volume Brinzolamide API or critical intermediates. However, for large-scale, cost-competitive bulk API, these regions are not currently significant players in the global market.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website Section on DMFs - Actual URL would be specific to FDA's DMF guidance pages] [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website Section on GMP - Actual URL would be specific to EMA's GMP guidance pages] [3] U.S. Patent 5,378,704. (1994). Thienothiazine derivatives and their use as carbonic anhydrase inhibitors. Filed: [Original Filing Date], Granted: [Grant Date], Expired: [Expiry Date - approx. 2010]. (Specific patent details and expiry dates may vary by jurisdiction and can be subject to extensions or challenges).